Recruiting
Non-small cell lung cancer stage III+1
RecruitingStudy of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer stage IIINon-small cell lung cancer stage II
- Substances:CarboplatinCisplatin+4
Countries:
France
France- Participants:18–64 years
- Substances:Carboplatin



